超小剂量地西他滨治疗中危-1型骨髓增生异常综合征10例的临床观察

发布时间：2018-12-28 11:30

【摘要】：目的探讨超小剂量地西他滨治疗中危-1型骨髓增生异常综合征的疗效及副反应。方法收集2016年1月至2017年1月中国医科大学附属盛京医院血液科10例中危-1型骨髓增生异常综合征患者的临床资料。所有患者接受皮下注射地西他滨10 mg/d,第1~3天,第8、15、22天。32 d为1个疗程。评估其疗效及副反应。结果 6例例存在MDS相关基因突变。1个疗程结束时4例获得了临床改善,其中1例部分缓解(PR),3例血液学改善(HI),6例疾病稳定(SD)。3例患者完成3个疗程治疗,疗效评估显示,2例获得了临床改善,1例(33.3%)完全缓解(CR),1例血液学改善,1例SD。出现骨髓抑制4例,白细胞减少1例,贫血1例,血小板减少3例;2例出现严重的血小板减少。结论超小剂量地西他滨治疗中危-1型骨髓增生异常综合征安全有效。
[Abstract]:Objective to evaluate the efficacy and side effects of ultra-low-dose dietabine in the treatment of moderate-risk-1 myelodysplastic syndromes. Methods from January 2016 to January 2017, the clinical data of 10 patients with type 1 myelodysplastic syndromes (MDS) in the Department of Hematology of Shengjing Hospital affiliated to China Medical University were collected. All patients were subcutaneously injected with desitabine for 10 mg/d, on day 1, 3, 815, 22 days, and 32 days as a course of treatment. Evaluate its curative effect and side effect. Results 6 cases had MDS related gene mutation, 4 cases had clinical improvement at the end of one course of treatment, and 1 case had partial remission (PR), 3 cases had hematological improvement (HI),. 6 patients with stable (SD). Completed 3 courses of treatment. The evaluation of curative effect showed that 2 cases had clinical improvement, 1 case (33.3%) had complete remission of (CR), 1 case had hematological improvement, and 1 case had SD.. Bone marrow suppression occurred in 4 cases, leukopenia in 1 case, anemia in 1 case, thrombocytopenia in 3 cases, and severe thrombocytopenia in 2 cases. Conclusion it is safe and effective to treat medium-risk-1 myelodysplastic syndrome with low dose of dicitabine.
【作者单位】：中国医科大学附属盛京医院血液科;
【基金】：中国医科大学附属盛京医院精准医学项目资助
【分类号】：R551.3

【相似文献】